Here is a data-driven look at Divis Laboratories Ltd. (DIVISLAB), covering financial performance, valuation, and shareholding trends.
Divis Laboratories Revenue Trend
For FY2025, Divis Laboratories Ltd. recorded revenue of ₹9,712 Cr. That's 18.7% higher than the ₹8,184 Cr it brought in during FY2024.
Stepping back, the 10-year revenue CAGR of 12.0% tells a positive story. Divis Laboratories Ltd. has been growing at a solid clip.
With a top line of ₹9,712 Cr, Divis Laboratories Ltd. operates at a mid-sized scale within the pharmaceuticals sector.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹9,712 Cr | +18.7% |
| FY2024 | ₹8,184 Cr | +0.9% |
| FY2023 | ₹8,112 Cr | -10.6% |
| FY2022 | ₹9,074 Cr | +29.0% |
| FY2021 | ₹7,032 Cr | — |
View Divis Laboratories Ltd.'s full 10-year revenue trend with CAGR analysis →
Divis Laboratories Profitability
Year-over-year, net profit grew 36.9% from ₹1,600 Cr to ₹2,191 Cr in FY2025 for Divis Laboratories Ltd..
Margins moved in the right direction, with net margin rising to 22.6% from 19.6%.
Looking at per-share numbers, diluted EPS was ₹82.53 in FY2025 — up from ₹60.27.
Is Divis Laboratories Undervalued
The P/E Ratio valuation pegs Divis Laboratories Ltd.'s fair value at ₹5,333, which is 18.9% downside from the current price.
Divis Laboratories Ltd. shares are currently trading at ₹6,576.50.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹5,333 | 18.9% downside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Divis Laboratories Ltd. with detailed assumptions →
Divis Laboratories Shareholding Pattern
The promoter group has maintained its 51.9% holding through the last 4 quarters.
As of March 2026, FIIs own 20.3% of the company — up from 19.7% a year earlier.
As of March 2026, DIIs own 19.2% of the company — up from 19.1% a year earlier.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 51.9% | 20.3% | 19.2% | 8.6% |
| Dec 2025 | 51.9% | 20.1% | 19.3% | 8.8% |
| Sep 2025 | 51.9% | 19.4% | 19.8% | 9.0% |
| Jun 2025 | 51.9% | 19.7% | 19.1% | 9.3% |
Track quarterly shareholding changes for Divis Laboratories Ltd. →
Divis Laboratories Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
Total assets stood at ₹169.32B at the end of FY2025, up 9.5% from ₹154.70B a year earlier.
Property, Plant & Equipment is the largest block at 38.1%, followed by Other Assets at 23.8% and Inventories at 19.1%.
Equity makes up 88.4% of liabilities and equity, with debt at 0.0% and operating liabilities at 11.6%. Over the year, debt is up 33.3% and equity is up 10.3%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 4.15B |
| Receivables | 27.31B |
| Inventories | 32.36B |
| Property, Plant & Equipment | 64.59B |
| Investments | 650.00M |
| Intangibles & Goodwill | 40.00M |
| Other Assets | 40.22B |
| Category | Value |
|---|---|
| Equity | 149.69B |
| Short-term Debt | 20.00M |
| Long-term Debt | 20.00M |
| Trade Payables | 9.10B |
| Other Liabilities | 10.49B |
Divis Laboratories at a Glance
In summary, Divis Laboratories Ltd. (DIVISLAB) presents the following picture for fundamental analysts.
Revenue of ₹9,712 Cr in FY2025, up 18.7% year-over-year.
Long-term revenue has been compounding at 12.0% annually over 10 years.
The company is profitable, with a net margin of 22.6% and net income of ₹2,191 Cr.
The P/E Ratio model implies 18.9% downside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
For the complete 10-year financial history with interactive charts and growth analysis, explore Divis Laboratories Ltd.'s detailed profile on Craytheon.